Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper
Allergy2020Vol. 76(3), pp. 677–688
Citations Over TimeTop 1% of 2020 papers
Ludger Klimek, Marek Jutel, Jean Bousquet, Ioana Agache, Cezmi A. Akdiş, Valérie Hox, Philippe Gevaert, Peter Valentin Tomazic, Carmen Rondón, Cemal Cingi, Sanna Toppila‐Salmi, Aspasia Karavelia, Banu Bozkurt, Ulrike Förster‐Ruhrmann, Sven Becker, Adam Chaker, Barbara Wollenberg, Ralph Mösges, Tilman Huppertz, Jan Hagemann, Claus Bachert, Wytske J. Fokkens
Abstract
Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.
Related Papers
- → Chronic rhinosinusitis and bacterial biofilms(2006)82 cited
- → Chronic Rhinosinusitis Phenotypes: An Approach to Better Medical Care for Chronic Rhinosinusitis(2016)25 cited
- → Nasal IL-25 predicts the response to oral-corticosteroid in chronic rhinosinusitis with nasal polyps (CRSwNP)(2018)1 cited
- → Functional endoscopic sinus surgery for chronic rhinosinusitis(2003)20 cited
- → P511 HEALTH MANAGEMENT STRATEGIES IN CHRONIC RHINOSINUSITIS: A REAL-WORLD EXPERIENCE(2020)